article thumbnail

Symvess: Humacyte’s FDA-Approved Bioengineered Solution for Vascular Trauma

XTalks

Manufactured using vascular smooth muscle cells derived from human aortic tissue, Symvess offers a novel solution for patients with traumatic vascular injuries. Symvess is a one-time, single-use, acellular tissue-engineered vessel (ATEV) composed of human extracellular matrix proteins.

article thumbnail

US FDA approves Kamada’s application to manufacture Cytogam

Pharmaceutical Technology

The US Food and Drug Administration (FDA) approved Kamada’s application to manufacture Cytogam (cytomegalovirus immune globulin intravenous [human]) at its facility located in Beit Kama, Israel. It is claimed to be the only immunoglobulin (IgG) product to receive FDA approval for this indication.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Krystal Biotech receives FDA approval for DEB topical gene therapy

Pharmaceutical Technology

An excipient gel applied topically is a key component of the therapy, which is supplied by Krystal’s client, Berkshire Sterile Manufacturing (BSM). BSM quality assurance vice-president Debbie Smith stated: “This approval is a testament to BSM’s unwavering commitment to quality and upholding cGMP guidelines. “We

article thumbnail

FDA approves IntelGenx’s Rizafilm for acute migraine treatment

Pharmaceutical Technology

IntelGenx’s president and CFO Andre Godin said that following successful pre-approval inspection of the company’s Montreal manufacturing facility by the FDA, the company is excited to soon introduce the first oral thin film for the treatment of acute migraines in the US.

article thumbnail

Top 30 New Medical Devices of 2024

XTalks

TriClip G4 System Manufacturer/developer : Abbott Medical Date of FDA approval : April 1, 2024 Approved for : Tricuspid regurgitation (TR). Date of FDA approval : March 29, 2024 Approved for : To detect exposure to human parvovirus B19. TriClip size comparison photo. Photo courtesy of Abbott Medical.

article thumbnail

Novartis secures FDA approval for Pluvicto production at US plant

Pharmaceutical Technology

Novartis has received the US FDA approval to commercially manufacture Pluvicto at its new RLT manufacturing facility.

article thumbnail

Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO™ (pralsetinib)

Pharma Mirror

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib).